LOPRESOR 50MG TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

METOPROLOL TARTRATE

Pieejams no:

NOVARTIS PHARMACEUTICALS CANADA INC

ATĶ kods:

C07AB02

SNN (starptautisko nepatentēto nosaukumu):

METOPROLOL

Deva:

50MG

Zāļu forma:

TABLET

Kompozīcija:

METOPROLOL TARTRATE 50MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100/500

Receptes veids:

Prescription

Ārstniecības joma:

BETA-ADRENERGIC BLOCKING AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0111923002; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2019-08-14

Produkta apraksts

_ _
_ _
_Page 1 of 42_
PRODUCT MONOGRAPH
PR
LOPRESOR
®
(metoprolol tartrate)
50 mg and 100 mg tablets
100 mg and 200 mg slow-release tablets
5 mL ampoules (1 mg/mL)
β-Adrenergic Receptor Blocking Agent
Novartis Pharmaceuticals Canada Inc.
385 Bouchard boulevard
Dorval, Quebec
H9S 1A9
Date of Preparation:
June 21, 1977
Date of Revision:
April 14, 2020
Submission Control No: 235180
LOPRESOR and LOPRESOR SR are Registered Trademarks
_ _
_ _
_Page 2 of 42_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
............................................................23
STORAGE AND STABILITY
..........................................................................................26
SPECIAL HANDLING INSTRUCTIONS
.......................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................27
PART II: SCIENTIFIC INFORMATION
...............................................................................28
PHARMACEUTICAL INFORMATION
..................